Literature DB >> 23065518

A polymorphism in the 3'-untranslated region of the NPM1 gene causes illegitimate regulation by microRNA-337-5p and correlates with adverse outcome in acute myeloid leukemia.

Chi Keung Cheng1, Tsz Ki Kwan, Chi Ying Cheung, Kitty Ng, Pei Liang, Suk Hang Cheng, Natalie P H Chan, Rosalina K L Ip, Raymond S M Wong, Vincent Lee, Chi Kong Li, Sze Fai Yip, Margaret H L Ng.   

Abstract

Nucleophosmin, encoded by NPM1, is a haploinsufficient suppressor in hematologic malignancies. NPM1 mutations are mostly found in acute myeloid leukemia patients with normal karyotype and associated with favorable prognosis. A polymorphic nucleotide T deletion with unknown significance is present in the NPM1 3'-untranslated region. Here, we showed that the homozygous nucleotide T deletion was associated with adverse outcomes and could independently predict shortened survival in patients with de novo acute myeloid leukemia. Mechanistically, we demonstrated that the nucleotide T deletion created an illegitimate binding NPM1 for miR-337-5p, which was widely expressed in different acute myeloid leukemia subtypes and inhibited NPM1 expression. Accordingly, NPM1 levels were found to be significantly reduced and correlated with miR-337-5p levels in patients carrying a homozygous nucleotide T-deletion genotype. Together, our findings uncover a microRNA-mediated control of NPM1 expression that contributes to disease heterogeneity and suggest additional prognostic values of NPM1 in acute myeloid leukemia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23065518      PMCID: PMC3669448          DOI: 10.3324/haematol.2012.073015

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  24 in total

1.  Specificity of microRNA target selection in translational repression.

Authors:  John G Doench; Phillip A Sharp
Journal:  Genes Dev       Date:  2004-03-10       Impact factor: 11.361

Review 2.  Nucleophosmin and cancer.

Authors:  Silvia Grisendi; Cristina Mecucci; Brunangelo Falini; Pier Paolo Pandolfi
Journal:  Nat Rev Cancer       Date:  2006-07       Impact factor: 60.716

3.  The role of site accessibility in microRNA target recognition.

Authors:  Michael Kertesz; Nicola Iovino; Ulrich Unnerstall; Ulrike Gaul; Eran Segal
Journal:  Nat Genet       Date:  2007-09-23       Impact factor: 38.330

4.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

Authors:  Brunangelo Falini; Cristina Mecucci; Enrico Tiacci; Myriam Alcalay; Roberto Rosati; Laura Pasqualucci; Roberta La Starza; Daniela Diverio; Emanuela Colombo; Antonella Santucci; Barbara Bigerna; Roberta Pacini; Alessandra Pucciarini; Arcangelo Liso; Marco Vignetti; Paola Fazi; Natalia Meani; Valentina Pettirossi; Giuseppe Saglio; Franco Mandelli; Francesco Lo-Coco; Pier-Giuseppe Pelicci; Massimo F Martelli
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

5.  Secreted-frizzled related protein 1 is a transcriptional repression target of the t(8;21) fusion protein in acute myeloid leukemia.

Authors:  Chi Keung Cheng; Libby Li; Suk Hang Cheng; Kitty Ng; Natalie P H Chan; Rosalina K L Ip; Raymond S M Wong; Matthew M K Shing; Chi Kong Li; Margaret H L Ng
Journal:  Blood       Date:  2011-10-26       Impact factor: 22.113

Review 6.  Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia.

Authors:  Soheil Meshinchi; Robert J Arceci
Journal:  Oncologist       Date:  2007-03

7.  Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

Authors:  Konstanze Döhner; Richard F Schlenk; Marianne Habdank; Claudia Scholl; Frank G Rücker; Andrea Corbacioglu; Lars Bullinger; Stefan Fröhling; Hartmut Döhner
Journal:  Blood       Date:  2005-07-28       Impact factor: 22.113

8.  Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution.

Authors:  Wen-Chien Chou; Jih-Luh Tang; Liang-In Lin; Ming Yao; Woei Tsay; Chien-Yuan Chen; Shang-Ju Wu; Chi-Fei Huang; Rong-Jing Chiou; Mei-Hsuan Tseng; Dong-Tsamn Lin; Kai-Hsin Lin; Yao-Chang Chen; Hwei-Fang Tien
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

9.  Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.

Authors:  Ramiro Garzon; Michela Garofalo; Maria Paola Martelli; Roger Briesewitz; Lisheng Wang; Cecilia Fernandez-Cymering; Stefano Volinia; Chang-Gong Liu; Susanne Schnittger; Torsten Haferlach; Arcangelo Liso; Daniela Diverio; Marco Mancini; Giovanna Meloni; Robin Foa; Massimo F Martelli; Cristina Mecucci; Carlo M Croce; Brunangelo Falini
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-28       Impact factor: 11.205

10.  Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.

Authors:  R J Mayer; R B Davis; C A Schiffer; D T Berg; B L Powell; P Schulman; G A Omura; J O Moore; O R McIntyre; E Frei
Journal:  N Engl J Med       Date:  1994-10-06       Impact factor: 91.245

View more
  7 in total

1.  miR-148b-3p, miR-337-5p and miR-423-5p expression in alveolar ridge atrophy and their roles in the proliferation and apoptosis of OMMSCs.

Authors:  Sefei Yang; Jun Guo; Lei Zhou; Helin Xing; Xianli Wang; Chaofang Dong
Journal:  Exp Ther Med       Date:  2018-10-11       Impact factor: 2.447

Review 2.  MicroRNA binding site polymorphisms as biomarkers in cancer management and research.

Authors:  Monica Cipollini; Stefano Landi; Federica Gemignani
Journal:  Pharmgenomics Pers Med       Date:  2014-07-23

Review 3.  MicroRNA-binding site polymorphisms in hematological malignancies.

Authors:  Agnieszka Dzikiewicz-Krawczyk
Journal:  J Hematol Oncol       Date:  2014-11-25       Impact factor: 17.388

Review 4.  The role of noncoding mutations in blood cancers.

Authors:  Sunniyat Rahman; Marc R Mansour
Journal:  Dis Model Mech       Date:  2019-11-26       Impact factor: 5.758

5.  Polymorphisms in microRNA target sites modulate risk of lymphoblastic and myeloid leukemias and affect microRNA binding.

Authors:  Agnieszka Dzikiewicz-Krawczyk; Anna Macieja; Ewa Mały; Danuta Januszkiewicz-Lewandowska; Maria Mosor; Marta Fichna; Ewa Strauss; Jerzy Nowak
Journal:  J Hematol Oncol       Date:  2014-06-02       Impact factor: 17.388

6.  Evaluation of DNMT3A genetic polymorphisms as outcome predictors in AML patients.

Authors:  Xiao-Qing Yuan; Dao-Yu Zhang; Han Yan; Yong-Long Yang; Ke-Wei Zhu; Yan-Hong Chen; Xi Li; Ji-Ye Yin; Xiao-Lin Li; Hui Zeng; Xiao-Ping Chen
Journal:  Oncotarget       Date:  2016-09-13

7.  Rs12976445 Polymorphism Is Associated with Post-Ablation Recurrence of Atrial Fibrillation by Modulating the Expression of MicroRNA-125a and Interleukin-6R.

Authors:  Xue-Bin Shen; Shao-Hong Zhang; Hai-Yang Li; Xi-Di Chi; Ling Jiang; Qi-Lei Huang; Shang-Hua Xu
Journal:  Med Sci Monit       Date:  2018-09-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.